| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Department of Pathology and Anatomical Sciences, Ellis Fischel Cancer Center [S. H. W., F. R., H. S., P. S. Y., T. H-M. H.] and Department of Computer Engineering and Computer Science [J. H., C-R. S.], University of Missouri, Columbia, Missouri 65203; Department of Zoology, National Chung Hsing University, Taiwan, Republic of China [C-M. C.]; Cancer Research Campaign Department of Medical Oncology, Cancer Research Campaign Beatson Laboratories, University of Glasgow, Glasgow G61 1BD, United Kingdom [G. S., R. B.]; Department of Obstetrics and Gynecology and Reproductive Biology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115 [S-W. N.]; and Medical Sciences, Indiana University School of Medicine, Bloomington, Indiana 47405 [K. P. N.]
Purpose: The purpose of this study was to profile methylation alterations of CpG islands in ovarian tumors and to identify candidate markers for diagnosis and prognosis of the disease.
Experimental Design: A global analysis of DNA methylation using a novel microarray approach called differential methylation hybridization was performed on 19 patients with stage III and IV ovarian carcinomas.
Results: Hierarchical clustering identified two groups of patients with distinct methylation profiles. Tumors from group 1 contained high levels of concurrent methylation, whereas group 2 tumors had lower tumor methylation levels. The duration of progression-free survival after chemotherapy was significantly shorter for patients in group 1 compared with group 2 (P < 0.001). Differential methylation in tumors was independently confirmed by methylation-specific PCR.
Conclusions: The data suggest that a higher degree of CpG island methylation is associated with early disease recurrence after chemotherapy. The differential methylation hybridization assay also identified a select group of CpG island loci that are potentially useful as epigenetic markers for predicting treatment outcome in ovarian cancer patients.
This article has been cited by other articles:
|
|
 |
|
  O. W. S. YAP, G. BHAT, L. LIU, and T. O. TOLLEFSBOL Epigenetic Modifications of the Estrogen Receptor {beta} Gene in Epithelial Ovarian Cancer Cells Anticancer Res, January 1, 2009; 29(1): 139 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Li, H.-i. H. Paik, C. Balch, Y. Kim, L. Li, T. H-M. Huang, K. P. Nephew, and S. Kim Enriched transcription factor binding sites in hypermethylated gene promoters in drug resistant cancer cells Bioinformatics, August 15, 2008; 24(16): 1745 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Sarkaria, G. J. Kitange, C. D. James, R. Plummer, H. Calvert, M. Weller, and W. Wick Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma Clin. Cancer Res., May 15, 2008; 14(10): 2900 - 2908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Carvalho, C. Jeronimo, M. M. Kim, R. Henrique, Z. Zhang, M. O. Hoque, S. Chang, M. Brait, C. S. Nayak, W.-W. Jiang, et al. Evaluation of Promoter Hypermethylation Detection in Body Fluids as a Screening/Diagnosis Tool for Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., January 1, 2008; 14(1): 97 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Zighelboim, P. J. Goodfellow, A. P. Schmidt, K. C. Walls, M. A. Mallon, D. G. Mutch, P. S. Yan, T. H.-M. Huang, and M. A. Powell Differential Methylation Hybridization Array of Endometrial Cancers Reveals Two Novel Cancer-Specific Methylation Markers Clin. Cancer Res., May 15, 2007; 13(10): 2882 - 2889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Shi, J. Guo, D. J. Duff, F. Rahmatpanah, R. Chitima-Matsiga, M. Al-Kuhlani, K. H. Taylor, O. Sjahputera, M. Andreski, J. E. Wooldridge, et al. Discovery of novel epigenetic markers in non-Hodgkin's lymphoma Carcinogenesis, January 1, 2007; 28(1): 60 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. K. Ibrahim, N. P. Thorne, K. Baird, N. L. Barbosa-Morais, S. Tavare, V. P. Collins, A. H. Wyllie, M. J. Arends, and J. D. Brenton MMASS: an optimized array-based method for assessing CpG island methylation Nucleic Acids Res., November 6, 2006; 34(20): e136 - e136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Ibanez de Caceres, E. Dulaimi, A. M. Hoffman, T. Al-Saleem, R. G. Uzzo, and P. Cairns Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res., May 15, 2006; 66(10): 5021 - 5028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Wei, C. Balch, H. H. Paik, Y.-S. Kim, R. L. Baldwin, S. Liyanarachchi, L. Li, Z. Wang, J. C. Wan, R. V. Davuluri, et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin. Cancer Res., May 1, 2006; 12(9): 2788 - 2794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Lyko and R. Brown DNA Methyltransferase Inhibitors and the Development of Epigenetic Cancer Therapies J Natl Cancer Inst, October 19, 2005; 97(20): 1498 - 1506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Teodoridis, J. Hall, S. Marsh, H. D. Kannall, C. Smyth, J. Curto, N. Siddiqui, H. Gabra, H. L. McLeod, G. Strathdee, et al. CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian Cancer Cancer Res., October 1, 2005; 65(19): 8961 - 8967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Balch, P. Yan, T. Craft, S. Young, D. G. Skalnik, T. H-M. Huang, and K. P. Nephew Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer Mol. Cancer Ther., October 1, 2005; 4(10): 1505 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. van Doorn, W. H. Zoutman, R. Dijkman, R. X. de Menezes, S. Commandeur, A. A. Mulder, P. A. van der Velden, M. H. Vermeer, R. Willemze, P. S. Yan, et al. Epigenetic Profiling of Cutaneous T-Cell Lymphoma: Promoter Hypermethylation of Multiple Tumor Suppressor Genes Including BCL7a, PTPRG, and p73 J. Clin. Oncol., June 10, 2005; 23(17): 3886 - 3896. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Laird Cancer epigenetics Hum. Mol. Genet., April 15, 2005; 14(suppl_1): R65 - R76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Hartmann, K. H. Lu, G. P. Linette, W. A. Cliby, K. R. Kalli, D. Gershenson, R. C. Bast, J. Stec, N. Iartchouk, D. I. Smith, et al. Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy Clin. Cancer Res., March 15, 2005; 11(6): 2149 - 2155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Muller, S. Millinger, H. Fiegl, G. Goebel, L. Ivarsson, A. Widschwendter, E. Muller-Holzner, C. Marth, and M. Widschwendter Analysis of Methylated Genes in Peritoneal Fluids of Ovarian Cancer Patients: A New Prognostic Tool Clin. Chem., November 1, 2004; 50(11): 2171 - 2173. [Full Text] [PDF]
|
|
|
|
|
|
N. P. Carter and D. Vetrie Applications of genomic microarrays to explore human chromosome structure and function Hum. Mol. Genet., October 1, 2004; 13(suppl_2): R297 - R302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. I. de Caceres, C. Battagli, M. Esteller, J. G. Herman, E. Dulaimi, M. I. Edelson, C. Bergman, H. Ehya, B. L. Eisenberg, and P. Cairns Tumor Cell-Specific BRCA1 and RASSF1A Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients Cancer Res., September 15, 2004; 64(18): 6476 - 6481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Dulaimi, J. Hillinck, I. I. de Caceres, T. Al-Saleem, and P. Cairns Tumor Suppressor Gene Promoter Hypermethylation in Serum of Breast Cancer Patients Clin. Cancer Res., September 15, 2004; 10(18): 6189 - 6193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gifford, J. Paul, P. A. Vasey, S. B. Kaye, and R. Brown The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients Clin. Cancer Res., July 1, 2004; 10(13): 4420 - 4426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Terasawa, S. Sagae, M. Toyota, K. Tsukada, K. Ogi, A. Satoh, H. Mita, K. Imai, T. Tokino, and R. Kudo Epigenetic Inactivation of TMS1/ASC in Ovarian Cancer Clin. Cancer Res., March 15, 2004; 10(6): 2000 - 2006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. J. Issa Methylation and Prognosis: Of Molecular Clocks and Hypermethylator Phenotypes Clin. Cancer Res., August 1, 2003; 9(8): 2879 - 2881. [Full Text] [PDF]
|
|
|
|
|
|
H. Shi, S. H. Wei, Y.-W. Leu, F. Rahmatpanah, J. C. Liu, P. S. Yan, K. P. Nephew, and T. H.-M. Huang Triple Analysis of the Cancer Epigenome: An Integrated Microarray System for Assessing Gene Expression, DNA Methylation, and Histone Acetylation Cancer Res., May 1, 2003; 63(9): 2164 - 2171. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
